Core Viewpoint - Morgan Stanley indicates a renewed interest in Chinese assets as the market shifts away from the dominance of dollar assets, redefining the Chinese stock market as a growth-oriented market [1][4]. Economic Policy Outlook - The macroeconomic policy for 2026 is expected to maintain a "moderate expansion" tone, with a slight increase in the broad fiscal deficit focusing on technology independence and infrastructure [2][5]. - Monetary policy will align with fiscal efforts, adopting a "moderately loose" strategy, likely relying more on targeted tools such as relending and PSL to support the economy [2][5]. Market Valuation and Investment Strategy - The Chinese stock market is undergoing a "structural valuation repair" process, with significant recovery in valuations, particularly in the Hong Kong Hang Seng Index and the MSCI China Index, which have seen over a 30% recovery in price-to-earnings ratios [3][6]. - Global investors are changing their perception of the Chinese stock market from one lacking clear growth potential to one with growth opportunities, especially in sectors like artificial intelligence, new consumption, automation, and robotics [3][6]. - The year 2026 is anticipated to be a transition from "valuation repair" to "profit-driven" growth, with limited upside for stock indices and moderate profit growth expected [3][6]. - Investment strategies should focus on high-quality internet and technology leaders while also including some high-dividend assets, employing a "barbell strategy" to balance risk and return [3][6].

Core Insights - The article highlights a significant influx of capital into the Hong Kong innovative pharmaceutical sector, driven by southbound funds and ETF investments, indicating strong market confidence in Chinese innovative drug companies [4][12]. Fund Flows - On September 11, southbound funds purchased HKD 18.989 billion worth of Hong Kong stocks, with innovative pharmaceuticals accounting for six of the top ten active stocks, totaling a net buy of HKD 2.929 billion, which represents 36.07% of the top ten net buy scale [4][5]. - ETFs also saw substantial inflows, with a total net inflow of HKD 15.558 billion on the same day, where the pharmaceutical index captured eight spots in the top 30, with innovative pharmaceutical indices collectively attracting HKD 6.183 billion, making up 39.74% of the total inflow [6][8]. Performance Metrics - The Hong Kong innovative pharmaceutical index has shown a year-to-date increase of 107.29%, with a price-to-earnings (P/E) ratio at a historical high, indicating a strong performance but also raising caution regarding potential overvaluation [2][12]. - The article notes that since 2025, there have been 540 business development (BD) transactions globally in innovative drugs, with Chinese companies involved in 83 transactions, amounting to USD 84.531 billion, which is 51.73% of the global total [12]. Investor Sentiment - Global funds are increasingly allocating resources to Chinese assets, with a notable rise in hedge fund positions in China, reaching a two-year high, reflecting a positive outlook on the Chinese market [13][14]. - Both Goldman Sachs and Morgan Stanley emphasize that breakthroughs in technology and supportive policies in China are key factors attracting foreign investment [14].